Çмú´ëȸ ¹ßÇ¥ ¿¬Á¦ ÃÊ·Ï

¹ßÇ¥Çü½Ä : Á¢¼ö¹øÈ£ - 980088    HNOP 5-2 
ESTABLISHING IN-VIVO MOUSE MODELS FOR LARYNGOPHARYNGEAL REFLUX DISEASE: ACIDIC WATER AND N-ACETYL CYSTEINE INTERVENTION
DEPARTMENT OF OTORHINOLARYNGOLOGY-HEAD AND NECK SURGERY, KOREA UNIVERSITY MEDICINE
YOU YEON CHUNG, BYOUNGJAE KIM, KWANG-YOON JUNG, KYUNG HO OH, SOON-YOUNG KWON, JEONG-SOO WOO, JAE-GU CHO, SEUNG-KUK BAEK
¸ñÀû: Despite the increasing prevalence of laryngopharyngeal reflux disease (LPRD), its research has faced challenges due to the absence of objective diagnosis, controversies surrounding its molecular-biological etiology, and poorly understood mechanisms, compounded by the lack of suitable disease research models. Previous in-vitro models have simulated LPR through acid exposure, elucidating that the escalation of MMP-7 is triggered by reactive oxygen species (ROS), involving ERK and c-Jun in the pathogenesis. This study aims to establish in-vivo mouse models of LPRD by feeding acid and N-acetyl cysteine (NAC). ¹æ¹ý:Daily doses of acidic water, with/without concurrent NAC exposure, were formulated to induce LPRD symptoms in mice. Pharyngeal tissues were histologically evaluated and compared through immunohistochemistry (IHC) with E-cadherin, MMP-7, and its regulatory factors (ROS and its downstream mediators, including ERK and c-Jun) to confirm the establishment of an LPRD animal model. Additionally, the expressions of E-cad and MMP-7 in the pharyngeal mucosa of the mice were analyzed by immunoblotting. °á°ú:In the acid treatment group, a significant decrease in E-cadherin and a marked increase in MMP-7 expression were observed. MMP-7 regulatory factors were also elevated. In contrast, in the NAC treatment group, these effects were reversed. The immunoblotting results corresponded to these findings. °á·Ð:Comparison of in-vivo research results with previous in-vitro studies verified MMP-7 regulatory factors as therapeutic targets for LPRD. The administration of acidic water effectively induced LPRD, and NAC demonstrated practical efficacy as an MMP-7 inhibitor, potentially serving as an LPRD treatment.


[´Ý±â]